Standard dosage	80–160 mg every 12 hours
Contraindications	Absolute: Prolonged QT interval, significant bradycardia/heart block
	Relative: Congestive heart failure, significant left ventricular hypertrophy, significant renal impairment
Main drug interactions	Macrolides, quinolones, phenothiazines, antifungals (risk of QT prolongation)
Main side effects	Bradycardia, heart block, QT prolongation leading to torsade de pointes
Special points	Class III agent (potassium channel blocker) with significant beta-blocking activity. Not as effective for converting AF, but useful to maintain NSR.
	Not as effective for converting AF, but useful to maintain NSR.
	Especially useful in patients with ischemic heart disease.
Cost/cost-effectiveness	Generic (approximate cost $24 per month). First 5 doses generally administered inpatient to monitor QT interval, but variability in clinical practice.